Market access for cancer drugs and the role of health economics

Annals of Oncology

Volumn 18, Issue SUPPL. 3, 2007, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BICALUTAMIDE; CAPECITABINE; CETUXIMAB; DOCETAXEL; EXEMESTANE; GEMCITABINE; GOSERELIN; IMATINIB; IRINOTECAN; LETROZOLE; NAVELBINE; NEW DRUG; OXALIPLATIN; PACLITAXEL; PEMETREXED; RALTITREXED; TEGAFUR; TEMOZOLOMIDE; TRASTUZUMAB; ZOLEDRONIC ACID;

ARTICLE; AUSTRIA; BUDGET; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG MARKETING; ECONOMIC EVALUATION; EUROPE; FRANCE; FUNDING; HEALTH CARE; HEALTH CARE ACCESS; HEALTH ECONOMICS; HOSPITAL; NETHERLANDS; PRIORITY JOURNAL; REIMBURSEMENT; SPAIN; SWEDEN; SWITZERLAND; UNITED KINGDOM;

EID: 54349117527     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm101     Document Type: Article

References (13)

1. Garrison L, Towse A. The drug budget silo mentality in Europe: An overview. Value Health 2003; 6 (Suppl 1): S1-S9.
2. Pharmaceutical Price Controls in OECD Countries:IMplications of U.S. Consumers, Pricing, Research and Development, and Innovation. Washington, DC: Department of Commerce, International Trade Administration 2004.
3. Danzon PM, Furukawa MF. Prices and availability of pharmaceuticals: evidence from nine countries. Health Aff (Millwood) 2003; (Suppl): 521-536.
4. EUROMET 2004. The Influence of Economic Evaluation Studies on Health Care Decision-Making - A European Survey. Amsterdam, The Netherlands: IOS Press 2005 2004.
5. Phase 5 Report January 2007. PATIENTS W.A.I.T. Indicator Commissioned by EFPIA. IMS Global Consulting.
6. Guidelines for the pharmaceutical industry on preparation of submissions to the pharmaceutical benefits advisory board. Canberra, Australia: Commonwealth department of human services and health 1995.
7. Guidelines for economic evaluation of pharmaceuticals: Canada, 2nd edition. Ottawa, Ontario, Canada: CCOHTA 19977.
8. Bosanquet N, Sikora K. The economics of cancer care in the UK. Lancet Oncol 2004; 5(9): 568-574.
9. Roehrig C, Kimberley K. Health technology assessment in Canada and the G-7 countries: A comparative analysis of the role of HTA agencies in the decision making process. Health Canada Health Care System Division 2003.
10. International Society for Pharmacoeonomics & Outcomes Research. Country-Specific Pharmacoeconomic Guidelines. http://www.ispor.org/ PEguidelines/index.asp (May 2006, date last accessed).
11. Hirth RA et al. Willingness to pay for a quality-adjusted life year: In search of a standard. Med Decis Making 2000; 20(3): 332-342.
12. World Health Organisation. World Health Report 2002. Geneva, Switzerland: World Health Organisation 2002.
13. Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist 2006; 11(2): 90-95.